BACKGROUND: Depression is common among persons with the human immunodeficiency virus (HIV) and is associated with unfavorable outcomes. METHODS: A single-blind randomized controlled effectiveness trial at 3 Veterans Affairs HIV clinics (HIV Translating Initiatives for Depression Into Effective Solutions [HITIDES]). The HITIDES intervention consisted of an off-site HIV depression care team (a registered nurse depression care manager, pharmacist, and psychiatrist) that delivered up to 12 months of collaborative care backed by a Web-based decision support system. Participants who completed the baseline telephone interview were 249 HIV-infected patients with depression, of whom 123 were randomized to the intervention and 126 to usual care. Participant interview data were collected at baseline and at the 6- and 12-month follow-up visits. The primary outcome was depression severity measured using the 20-item Hopkins Symptom Checklist (SCL-20) and reported as treatment response (≥50% decrease in SCL-20 item score), remission (mean SCL-20 item score, <0.5), and depression-free days. Secondary outcomes were health-related quality of life, health status, HIV symptom severity, and antidepressant or HIV medication regimen adherence. RESULTS: Intervention participants were more likely to report treatment response (33.3% vs 17.5%) (odds ratio, 2.50; 95% confidence interval [CI], 1.37-4.56) and remission (22.0% vs 11.9%) (2.25; 1.11-4.54) at 6 months but not 12 months. Intervention participants reported more depression-free days during the 12 months (β = 19.3; 95% CI, 10.9-27.6; P < .001). Significant intervention effects were observed for lowering HIV symptom severity at 6 months (β = -2.6; 95% CI, -3.5 to -1.8; P < .001) and 12 months (β = -0.82; -1.6 to -0.07; P = .03). Intervention effects were not significant for other secondary outcomes. CONCLUSION: The HITIDES intervention improved depression and HIV symptom outcomes and may serve as a model for collaborative care interventions in HIV and other specialty physical health care settings where patients find their "medical home." TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00304915.
RCT Entities:
BACKGROUND:Depression is common among persons with the human immunodeficiency virus (HIV) and is associated with unfavorable outcomes. METHODS: A single-blind randomized controlled effectiveness trial at 3 Veterans Affairs HIV clinics (HIV Translating Initiatives for Depression Into Effective Solutions [HITIDES]). The HITIDES intervention consisted of an off-site HIV depression care team (a registered nurse depression care manager, pharmacist, and psychiatrist) that delivered up to 12 months of collaborative care backed by a Web-based decision support system. Participants who completed the baseline telephone interview were 249 HIV-infectedpatients with depression, of whom 123 were randomized to the intervention and 126 to usual care. Participant interview data were collected at baseline and at the 6- and 12-month follow-up visits. The primary outcome was depression severity measured using the 20-item Hopkins Symptom Checklist (SCL-20) and reported as treatment response (≥50% decrease in SCL-20 item score), remission (mean SCL-20 item score, <0.5), and depression-free days. Secondary outcomes were health-related quality of life, health status, HIV symptom severity, and antidepressant or HIV medication regimen adherence. RESULTS: Intervention participants were more likely to report treatment response (33.3% vs 17.5%) (odds ratio, 2.50; 95% confidence interval [CI], 1.37-4.56) and remission (22.0% vs 11.9%) (2.25; 1.11-4.54) at 6 months but not 12 months. Intervention participants reported more depression-free days during the 12 months (β = 19.3; 95% CI, 10.9-27.6; P < .001). Significant intervention effects were observed for lowering HIV symptom severity at 6 months (β = -2.6; 95% CI, -3.5 to -1.8; P < .001) and 12 months (β = -0.82; -1.6 to -0.07; P = .03). Intervention effects were not significant for other secondary outcomes. CONCLUSION: The HITIDES intervention improved depression and HIV symptom outcomes and may serve as a model for collaborative care interventions in HIV and other specialty physical health care settings where patients find their "medical home." TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00304915.
Authors: Alexander C Tsai; Dan H Karasic; Gwendolyn P Hammer; Edwin D Charlebois; Kathy Ragland; Andrew R Moss; James L Sorensen; James W Dilley; David R Bangsberg Journal: Am J Public Health Date: 2012-06-21 Impact factor: 9.308
Authors: David A Brent; Steven M Brunwasser; Steven D Hollon; V Robin Weersing; Gregory N Clarke; John F Dickerson; William R Beardslee; Tracy R G Gladstone; Giovanna Porta; Frances L Lynch; Satish Iyengar; Judy Garber Journal: JAMA Psychiatry Date: 2015-11 Impact factor: 21.596
Authors: Karen H Seal; Brian Borsari; Jennifer Tighe; Beth E Cohen; Kevin Delucchi; Benjamin J Morasco; Yongmei Li; Emily Sachs; Linda Abadjian; Erin C Watson; Jennifer K Manuel; Lea Vella; Jodie Trafton; Amanda Midboe Journal: Contemp Clin Trials Date: 2018-12-17 Impact factor: 2.226
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Bethany L DiPrete; Brian W Pence; Angela M Bengtson; Richard D Moore; David J Grelotti; Conall O'Cleirigh; Riddhi Modi; Bradley N Gaynes Journal: AIDS Behav Date: 2019-03
Authors: Kiana D Bess; Julie Adams; Melissa H Watt; Julie K O'Donnell; Bradley N Gaynes; Nathan M Thielman; Amy Heine; Anne Zinski; James L Raper; Brian W Pence Journal: AIDS Patient Care STDS Date: 2013-02-26 Impact factor: 5.078